ETR:MOR

MorphoSys - MOR News Today

€14.40

+0.14 (+0.98%)

(As of 03/23/2023 12:00 AM ET)

Add

Compare

Today's Range: €14.09
▼
€14.51
50-Day Range: €13.64
▼
€19.33
52-Week Range: €11.81
▼
€27.87

Volume: 115,668 shs
Average Volume: 153,687 shs
Market Capitalization: $491.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: €22.70

Get MorphoSys News Delivered to You Automatically

MOR Media Mentions By Week

MOR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MOR
News Sentiment
▼
0.00

0.39
▲
Average
Medical
News Sentiment

MOR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MOR Articles
This Week
▼
2

1
▲
MOR Articles
Average Week

Source

Source	Headline
	EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6) markets.businessinsider.com - March 24 at 12:41 PM
	MorphoSys (ETR:MOR) Given a €11.00 Price Target by JPMorgan Chase & Co. Analysts americanbankingnews.com - March 18 at 1:38 AM
	MorphoSys Full Year 2022 Earnings: Beats Expectations finance.yahoo.com - March 17 at 1:15 AM
	Angiotensin II Receptor Market Size 2023 Research Report by Manufacturing Process Analysis and Forecast till 2027 marketwatch.com - March 14 at 5:22 PM
	MorphoSys (ETR:MOR) PT Set at €11.00 by JPMorgan Chase & Co. americanbankingnews.com - March 14 at 3:12 AM
	MorphoSys Lays off 70 Employees as It Stops Preclinical Research marketwatch.com - March 2 at 1:13 PM
	FDA accepts for priority review Aldeyra's ADX-2191 application in retinal cancer msn.com - March 2 at 8:13 AM
	MorphoSys ends pre-clinical research in favor of clinical-stage cancer programs msn.com - March 2 at 8:13 AM
	Anti-CD19 Market is Booming Worldwide to Show Significant Growth over the Forecast 2023 to 2029 marketwatch.com - March 2 at 3:12 AM
	Skin Cancer Drugs Global Market Report 2023 uk.finance.yahoo.com - February 23 at 4:03 PM
	Telecoms, Financial Stocks Weigh Down European Equities in Wednesday Trading msn.com - February 15 at 1:12 PM
	Royalty Pharma plc: Royalty Pharma Reports Q4 and Full Year 2022 Results finanznachrichten.de - February 15 at 1:12 PM
	Germany stocks lower at close of trade; DAX down 0.11% msn.com - February 14 at 3:20 PM
	Anti-CD19 Market Insights-Industry changing aspects, New Technologies and Forecast to 2029 marketwatch.com - February 7 at 3:00 AM
	Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability uk.finance.yahoo.com - January 5 at 6:49 AM
	Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability uk.finance.yahoo.com - January 5 at 6:49 AM
	MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability finanznachrichten.de - January 5 at 6:49 AM
	MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability finanznachrichten.de - January 5 at 6:49 AM
	MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability finance.yahoo.com - January 5 at 6:49 AM
	European Equities Continue Strong Start to 2023 in Wednesday Trading msn.com - January 4 at 12:33 PM
	MorphoSys AG (NASDAQ:MOR) Q3 2022 Earnings Call Transcript finance.yahoo.com - December 28 at 12:16 AM
	MorphoSys CFO Sung Lee To Step Down In March 2023 markets.businessinsider.com - December 22 at 12:03 AM
	IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space \| DelveInsight nz.finance.yahoo.com - December 14 at 1:27 PM
	MorphoSys AG: Financial Calendar 2023 finance.yahoo.com - November 28 at 4:35 PM
	EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results markets.businessinsider.com - November 16 at 5:25 PM
	MorphoSys Shares Slide After Roche's Alzheimer's Drug Trial Fails marketwatch.com - November 15 at 3:00 PM
	Roche faces another setback in Alzheimer's as gantenerumab fails phase 3 trials, MorphoSys plunges 32% seekingalpha.com - November 15 at 3:00 PM
	Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab finance.yahoo.com - November 14 at 6:54 AM
	Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease uk.finance.yahoo.com - November 14 at 1:52 AM
	Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022 finance.yahoo.com - November 10 at 5:29 PM
	MorphoSys AG (ETR:MOR) most popular amongst individual investors who own 51% of the shares, institutions hold 45% finance.yahoo.com - November 8 at 2:18 AM
	MorphoSys Highlights Preliminary Data From Tulmimetostat Study Across Broad Array of Advanced Tumors finance.yahoo.com - October 28 at 4:19 PM
	European ADRs Climb in Tuesday Trading msn.com - October 4 at 1:48 PM
	MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings finance.yahoo.com - September 29 at 2:15 PM
	MORG.DE - MorphoSys AG \| Stock Price & Latest News \| Reuters reuters.com - September 2 at 6:02 PM
	MorphoSys AG: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters finanznachrichten.de - September 1 at 6:49 PM
	MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2022 Results - Earnings Call Transcript seekingalpha.com - August 6 at 5:42 PM
	DGAP-News: MorphoSys AG: Invitation to MorphoSys Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 markets.businessinsider.com - July 28 at 8:13 PM
	MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 finance.yahoo.com - July 28 at 8:13 PM
	MorphoSys AG: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 finanznachrichten.de - July 27 at 8:08 PM
	HIBio To Develop, Commercialize MorphoSys' Felzartamab, And TJ210 Outside Of Greater China nasdaq.com - June 15 at 10:01 AM
	MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio finance.yahoo.com - June 14 at 8:25 PM
	MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022 finance.yahoo.com - June 10 at 5:18 AM
	MorphoSys AG (MOR) Q1 2022 Earnings Call Transcript finance.yahoo.com - May 5 at 9:07 PM
	DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results markets.businessinsider.com - May 4 at 6:34 PM
	Here's How Criteo Fared In Q1 uk.investing.com - May 4 at 6:34 PM
	Morphosys triples Q1 loss as new subsidiary ramps up costs uk.investing.com - May 4 at 6:34 PM
	MorphoSys May Not Recover From Adventurous Constellation Buyout seekingalpha.com - May 4 at 6:34 PM
	MorphoSys AG Reports First Quarter 2022 Financial Results finance.yahoo.com - May 4 at 6:34 PM
	DGAP-News: MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update markets.businessinsider.com - March 16 at 8:47 PM

Get MorphoSys News Delivered to You Automatically

This page (ETR:MOR) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MorphoSys - MOR News Today

MOR Media Mentions By Week

MOR Media Sentiment

MOR News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info